Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 11;42(11):1808-1810.
doi: 10.1016/j.ccell.2024.10.005. Epub 2024 Oct 31.

Fertility outcomes post immune checkpoint inhibitor exposure

Emily C Harrold  1 , Martinique Ogle  1 , Erin O'Brien  1 , Callahan Wilde  1 , Jenna Sinopoli  1 , Jill Weiss  1 , Lauren Martino  2 , Anne Casson  2 , Hey-Joo Kang  3 , Michael Postow  1 , Andrea Cercek  4
Affiliations

Fertility outcomes post immune checkpoint inhibitor exposure

Emily C Harrold et al. Cancer Cell. .

Abstract

Harrold et al. evaluate the fertility impact of checkpoint inhibitor blockade (ICB), demonstrating that unlike in utero exposure, post-exposure conception appears to result in uncomplicated pregnancies and healthy progeny. They demonstrate contemporaneous monitoring of temporal female hormonal fluctuations before, on, and post ICB exposure and prior to successful embryo implantation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests E.H. has received funding from the Conquer Cancer ASCO Foundation. She has served as a consultant to Pfizer Ireland on one occasion in 2021 and to Takeda on one occasion in 2024. She reports educational grants from Merck and Amgen to attend GI ASCO 2020. M.P. has received personal fees for consulting from BMS, Merck, Novartis, Eisai, Pfizer, Chugai, Erasca, and Nektar. He reports institutional support from the following companies: RGenix, Infinity, BMS, Merck, Novartis, BioAtla, and Genentech. A.C. has served on advisory boards for the following companies: Abbvie, Amgen, Agenus, Daiichi Saynko, Janssen, GSK, Merck, Pfizer/Seagen Regeneron, and Roche. She has research funding from GSK and Pfizer/Seagen. She holds a pending patent for Neoadjuvant PD1 blockade in locally advanced mismatch repair deficient solid tumors.

Substances

LinkOut - more resources